Contact this trialFirst, we need to learn more about you.
Tumor Necrosis Factor (TNF) Inhibitor
Upadacitinib vs Adalimumab for Rheumatoid Arthritis
Recruiting1 awardPhase 3
Tampa, Florida
This trial will assess the safety and effectiveness of upadacitinib compared to adalimumab in treating RA when used with a stable dose of methotrexate. 480 participants will be enrolled in 250 sites across the world, and receive either upadacitinib or adalimumab randomly. Assessments and side effects will be monitored.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.